Twist Bioscience (TWST) Financials

$49.79 +0.62 (+1.26%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$50.06 +0.27 (+0.54%)

As of 04:48 AM Eastern

Annual Income Statements for Twist Bioscience

This table shows Twist Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	9/30/2017	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024	9/30/2025
Net Income / (Loss) Attributable to Common Shareholders	-59	-71	-108	-140	-152	-218	-205	-209	-78
Consolidated Net Income / (Loss)	-59	-71	-108	-140	-152	-218	-205	-209	-78
Net Income / (Loss) Continuing Operations	-59	-71	-108	-140	-152	-218	-205	-209	-78
Total Pre-Tax Income	-59	-71	-107	-140	-154	-228	-203	-208	-77
Total Operating Income	-58	-71	-109	-140	-153	-235	-217	-221	-136
Total Gross Profit	-13	-6.76	6.96	29	52	84	90	133	191
Total Revenue	11	25	54	90	132	204	245	313	377
Operating Revenue	11	25	54	90	132	204	245	313	377
Total Cost of Revenue	24	32	47	61	81	119	155	180	186
Operating Cost of Revenue	24	32	47	61	81	119	155	180	186
Total Operating Expenses	45	64	116	169	204	319	307	354	327
Selling, General & Admin Expense	26	43	80	103	136	213	190	218	247
Research & Development Expense	19	20	36	43	69	120	107	91	80
Other Operating Expenses / (Income)	-	-	0.00	0.00	-0.53	-14	-5.91	0.00	0.00
Impairment Charge	-	-	-	-	-	0.00	6.79	45	0.00
Restructuring Charge	-	-	-	-	0.00	0.00	9.38	0.00	0.00
Total Other Income / (Expense), net	-0.55	-0.44	1.47	0.53	-1.30	6.50	14	13	59
Interest & Investment Income	0.41	1.00	3.03	1.50	0.44	7.67	14	15	11
Other Income / (Expense), net	-0.06	-0.12	-0.27	-0.18	-1.37	-1.09	-0.67	-2.68	48
Income Tax Expense	0.28	0.24	0.29	0.38	-1.93	-10	1.15	0.56	0.72
Basic Earnings per Share	($24.49)	($25.51)	($3.92)	($3.57)	($3.15)	($4.04)	($3.60)	($3.60)	($1.30)
Weighted Average Basic Shares Outstanding	2.42M	2.79M	27.46M	39.19M	48.25M	53.89M	56.89M	58.02M	59.81M
Diluted Earnings per Share	($24.49)	($25.51)	($3.92)	($3.57)	($3.15)	($4.04)	($3.60)	($3.60)	($1.30)
Weighted Average Diluted Shares Outstanding	2.42M	2.79M	27.46M	39.19M	48.25M	53.89M	56.89M	58.02M	59.81M
Weighted Average Basic & Diluted Shares Outstanding	2.42M	2.79M	27.46M	39.19M	48.25M	56.57M	57.67M	59.36M	61.15M

This table shows Twist Bioscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-46	-43	-45	-86	-35	-32	-39	20	-27	-31	-44
Consolidated Net Income / (Loss)	-46	-43	-45	-86	-35	-32	-39	20	-27	-31	-44
Net Income / (Loss) Continuing Operations	-46	-43	-45	-86	-35	-32	-39	20	-27	-31	-44
Total Pre-Tax Income	-46	-43	-45	-85	-35	-31	-39	21	-27	-30	-44
Total Operating Income	-50	-47	-49	-89	-36	-35	-42	-30	-30	-33	-46
Total Gross Profit	25	29	31	35	38	43	46	51	51	54	57
Total Revenue	67	71	75	81	85	89	93	96	99	104	111
Operating Revenue	67	71	75	81	85	89	93	96	99	104	111
Total Cost of Revenue	42	43	44	46	46	46	47	45	48	50	54
Operating Cost of Revenue	42	43	44	46	46	46	47	45	48	50	54
Total Operating Expenses	75	76	80	124	74	77	88	81	81	87	103
Selling, General & Admin Expense	47	53	56	57	53	56	64	63	64	70	76
Research & Development Expense	24	23	24	22	21	21	24	18	17	17	20
Other Special Charges / (Income)	-	-	-	-	-	-	0.00	-	-	-	7.21
Total Other Income / (Expense), net	3.65	4.09	3.74	3.54	1.29	3.15	2.41	51	3.05	2.65	1.89
Interest & Investment Income	3.89	4.12	3.94	3.66	3.62	3.24	2.80	2.69	2.63	2.18	1.71
Other Income / (Expense), net	-0.25	-0.03	-0.20	-0.12	-2.30	-0.09	-0.39	48	0.25	0.47	0.18
Income Tax Expense	-0.22	0.12	0.35	0.19	-0.10	0.10	0.18	0.19	0.26	0.25	0.04
Basic Earnings per Share	($0.81)	($0.75)	($0.79)	($1.47)	($0.59)	($0.53)	($0.66)	$0.34	($0.45)	($0.50)	($0.71)
Weighted Average Basic Shares Outstanding	56.89M	57.50M	57.78M	58.15M	58.02M	59.16M	59.65M	60.00M	59.81M	61.08M	61.70M
Diluted Earnings per Share	($0.81)	($0.75)	($0.79)	($1.47)	($0.59)	($0.53)	($0.66)	$0.33	($0.44)	($0.50)	($0.71)
Weighted Average Diluted Shares Outstanding	56.89M	57.50M	57.78M	58.15M	58.02M	59.16M	59.65M	61.16M	59.81M	61.08M	61.70M
Weighted Average Basic & Diluted Shares Outstanding	57.67M	57.82M	58.23M	58.59M	59.36M	59.65M	59.92M	60.36M	61.15M	61.31M	62.27M

This table details how cash moves in and out of Twist Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	9/30/2017	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024	9/30/2025
Net Change in Cash & Equivalents	2.51	50	-34	47	373	-87	-91	-60	-44
Net Cash From Operating Activities	-51	-66	-88	-142	-112	-124	-142	-64	-48
Net Cash From Continuing Operating Activities	-51	-66	-88	-142	-113	-124	-142	-64	-48
Net Income / (Loss) Continuing Operations	-59	-71	-108	-140	-152	-218	-205	-209	-78
Consolidated Net Income / (Loss)	-59	-71	-108	-140	-152	-218	-205	-209	-78
Depreciation Expense	5.02	5.73	6.11	6.68	9.75	17	29	31	25
Non-Cash Adjustments To Reconcile Net Income	3.02	3.26	12	16	39	97	40	98	18
Changes in Operating Assets and Liabilities, net	-0.13	-4.22	3.00	-25	-9.38	-20	-6.92	15	-13
Net Cash From Investing Activities	-9.99	27	-105	-115	156	-233	51	-3.07	-25
Net Cash From Continuing Investing Activities	-9.99	27	-105	-115	156	-233	51	-3.07	-25
Purchase of Property, Plant & Equipment	-6.59	-3.69	-15	-9.87	-27	-102	-28	-5.08	-28
Purchase of Investments	-41	-3.52	-178	-203	-59	-218	-76	-52	-49
Divestitures	-	-	-	-	-	-	0.00	0.00	2.50
Sale and/or Maturity of Investments	37	35	88	98	242	100	155	54	50
Net Cash From Financing Activities	64	89	159	304	329	271	0.91	6.89	29
Net Cash From Continuing Financing Activities	64	89	159	304	329	271	0.91	6.89	29
Repurchase of Common Equity	0.00	-2.36	0.00	-2.42	-11	-7.75	-4.41	-3.98	-0.02
Issuance of Debt	2.17	-	-	-	-	-	0.00	0.00	15
Issuance of Common Equity	0.21	0.33	158	306	338	280	1.38	7.10	9.34
Other Financing Activities, net	-	-	2.70	3.43	4.94	-	3.94	3.77	4.21
Effect of Exchange Rate Changes	-	-	0.03	0.02	0.02	-0.32	-0.03	0.13	0.14
Cash Income Taxes Paid	0.01	0.18	0.29	0.17	0.10	0.25	0.42	0.34	0.68

This table details how cash moves in and out of Twist Bioscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-23	-20	-23	-4.18	-13	-5.07	-11	-9.04	-18	-34	-26
Net Cash From Operating Activities	-21	-23	-19	-6.38	-15	-21	-13	-1.40	-12	-25	-18
Net Cash From Continuing Operating Activities	-21	-23	-19	-6.38	-15	-21	-13	-1.40	-12	-25	-18
Net Income / (Loss) Continuing Operations	-46	-43	-45	-86	-35	-32	-39	20	-27	-31	-44
Consolidated Net Income / (Loss)	-46	-43	-45	-86	-35	-32	-39	20	-27	-31	-44
Depreciation Expense	8.50	8.17	8.30	8.30	6.66	6.38	6.40	6.07	6.00	6.19	6.41
Non-Cash Adjustments To Reconcile Net Income	22	11	14	58	14	12	21	-32	16	13	18
Changes in Operating Assets and Liabilities, net	0.44	0.53	3.46	13	-1.14	-8.19	-1.22	3.78	-6.98	-13	1.61
Net Cash From Investing Activities	-2.25	4.17	-5.24	-0.71	-1.29	-1.54	-1.43	-9.40	-12	-9.93	-13
Net Cash From Continuing Investing Activities	-2.25	4.17	-5.24	-0.71	-1.29	-1.54	-1.43	-9.40	-12	-9.93	-13
Purchase of Property, Plant & Equipment	-2.39	-1.51	-0.60	-0.97	-2.00	-2.27	-4.14	-9.17	-12	-9.97	-13
Purchase of Investments	-18	-18	-11	-1.75	-21	-21	-4.93	-2.73	-21	-21	-4.72
Sale and/or Maturity of Investments	18	24	6.00	2.00	22	21	7.65	-	21	21	5.00
Net Cash From Financing Activities	0.44	-1.47	1.83	2.91	3.63	18	3.20	1.83	5.57	0.30	4.14
Net Cash From Continuing Financing Activities	0.44	-1.47	1.83	2.91	3.63	18	3.20	1.83	5.57	0.30	4.14
Repurchase of Common Equity	-1.13	-2.42	-1.54	-0.01	-0.01	-0.01	-0.01	-0.00	-0.00	-0.00	-0.01
Issuance of Common Equity	0.17	0.95	1.32	2.92	5.68	2.95	0.77	1.83	3.79	0.30	1.79
Effect of Exchange Rate Changes	-0.05	0.12	-0.07	0.00	0.07	-0.05	0.10	-0.07	0.16	0.01	-0.01
Cash Income Taxes Paid	0.18	0.04	0.30	0.02	-0.02	0.00	0.01	0.01	0.66	0.18	0.47

This table presents Twist Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024	9/30/2025
Total Assets	116	187	399	702	961	776	614	642
Total Current Assets	96	160	335	546	596	424	347	333
Cash & Equivalents	81	47	94	466	379	286	226	183
Short-Term Investments	0.00	91	196	12	126	50	50	49
Accounts Receivable	5.42	12	26	29	40	44	35	57
Inventories, net	6.03	7.33	12	32	39	32	24	28
Prepaid Expenses	3.47	2.59	6.20	8.28	12	12	11	15
Plant, Property, & Equipment, net	12	21	25	44	139	132	103	102
Total Noncurrent Assets	7.79	6.02	39	111	225	220	165	207
Long-Term Investments	-	-	-	-	-	-	1.53	54
Goodwill	1.14	1.14	1.14	22	86	86	86	82
Intangible Assets	0.71	0.51	0.31	18	60	54	14	13
Other Noncurrent Operating Assets	5.94	4.38	37	71	80	80	63	57
Total Liabilities & Shareholders' Equity	116	187	399	702	961	776	614	642
Total Liabilities	27	35	63	121	172	153	142	169
Total Current Liabilities	19	30	36	63	91	73	71	91
Accounts Payable	7.53	9.76	4.83	15	20	14	1.63	11
Current Employee Benefit Liabilities	5.40	10	15	22	27	26	34	31
Other Current Liabilities	0.94	0.82	9.02	18	33	23	21	49
Total Noncurrent Liabilities	8.19	4.56	27	58	81	80	71	77
Noncurrent Deferred Revenue	-	-	-	-	-	-	0.00	15
Other Noncurrent Operating Liabilities	0.98	0.16	25	58	81	80	71	62
Commitments & Contingencies	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-201	152	336	581	789	623	473	473
Total Preferred & Common Equity	-201	152	336	581	789	623	473	473
Total Common Equity	-201	152	336	581	789	623	473	473
Common Stock	9.35	470	795	1,191	1,620	1,657	1,715	1,793
Retained Earnings	-211	-319	-458	-611	-828	-1,033	-1,242	-1,320
Accumulated Other Comprehensive Income / (Loss)	0.09	0.18	0.09	0.55	-1.84	-0.76	-0.52	-0.63

This table presents Twist Bioscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	12/31/2022	3/31/2023	6/30/2023	12/31/2023	3/31/2024	6/30/2024	12/31/2024	3/31/2025	6/30/2025	12/31/2025	3/31/2026
Total Assets	910	854	810	733	703	638	609	596	644	638	676
Total Current Assets	542	489	446	390	372	362	345	338	340	304	323
Cash & Equivalents	317	315	307	266	243	239	221	210	201	149	123
Short-Term Investments	122	72	50	45	50	50	49	47	49	49	49
Accounts Receivable	44	48	43	35	36	32	39	50	50	50	64
Inventories, net	45	40	36	31	30	28	24	21	26	33	34
Prepaid Expenses	14	14	9.46	13	12	12	12	10	13	23	54
Plant, Property, & Equipment, net	145	147	141	126	121	106	101	97	95	105	111
Total Noncurrent Assets	223	218	224	216	210	170	163	160	208	229	242
Long-Term Investments	-	-	-	-	-	-	-	-	54	54	68
Goodwill	86	86	86	86	86	86	86	86	82	82	82
Intangible Assets	58	57	56	53	52	15	14	14	14	13	13
Other Noncurrent Operating Assets	79	75	82	77	72	69	63	60	58	79	78
Total Liabilities & Shareholders' Equity	910	854	810	733	703	638	609	596	644	638	676
Total Liabilities	164	150	153	143	143	147	153	156	165	182	221
Total Current Liabilities	84	72	73	65	67	74	70	75	87	80	120
Accounts Payable	20	13	12	9.26	7.70	6.63	7.50	8.06	12	12	15
Current Employee Benefit Liabilities	23	24	27	21	25	32	22	25	29	19	27
Other Current Liabilities	30	23	23	21	20	21	20	22	27	26	78
Total Noncurrent Liabilities	80	78	80	78	75	73	83	81	78	102	101
Noncurrent Deferred Revenue	-	-	-	-	-	-	15	15	15	15	15
Other Noncurrent Operating Liabilities	80	78	80	78	75	73	68	66	63	87	86
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	746	704	658	590	560	491	456	440	478	456	455
Total Preferred & Common Equity	746	704	658	590	560	491	456	440	478	456	455
Total Common Equity	746	704	658	590	560	491	456	440	478	456	455
Common Stock	1,617	1,633	1,645	1,667	1,682	1,699	1,730	1,754	1,772	1,807	1,850
Retained Earnings	-870	-929	-987	-1,076	-1,122	-1,207	-1,274	-1,313	-1,292	-1,350	-1,394
Accumulated Other Comprehensive Income / (Loss)	-0.61	0.11	-0.64	-0.57	-0.66	-0.74	-0.65	-0.66	-0.86	-0.57	-0.64

This table displays calculated financial ratios and metrics derived from Twist Bioscience's official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	9/30/2017	9/30/2018	9/30/2019	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024	9/30/2025
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	136.16%	113.89%	65.67%	46.87%	53.83%	20.41%	27.69%	20.32%
EBITDA Growth	0.00%	-21.01%	-60.83%	-28.51%	-8.43%	-51.40%	11.36%	1.22%	66.96%
EBIT Growth	0.00%	-20.74%	-54.38%	-28.54%	-9.86%	-53.06%	7.65%	-2.60%	60.49%
NOPAT Growth	0.00%	-20.65%	-54.27%	-28.69%	-9.03%	-53.72%	7.50%	-1.69%	38.30%
Net Income Growth	0.00%	-20.11%	-51.14%	-29.96%	-8.70%	-43.24%	6.08%	-2.01%	62.79%
EPS Growth	0.00%	-4.17%	84.63%	8.93%	11.76%	-28.25%	10.89%	0.00%	63.89%
Operating Cash Flow Growth	0.00%	-28.97%	-32.91%	-61.77%	21.10%	-10.82%	-14.54%	55.01%	25.69%
Free Cash Flow Firm Growth	0.00%	0.00%	-18.49%	-59.42%	-25.98%	-114.59%	55.09%	58.70%	-39.27%
Invested Capital Growth	0.00%	0.00%	20.45%	134.92%	104.94%	172.14%	0.91%	-31.61%	-4.40%
Revenue Q/Q Growth	0.00%	0.00%	15.58%	22.75%	4.35%	10.51%	4.09%	6.02%	3.95%
EBITDA Q/Q Growth	0.00%	0.00%	-13.00%	5.80%	-13.66%	0.08%	2.32%	5.03%	11.20%
EBIT Q/Q Growth	0.00%	0.00%	-12.15%	5.11%	-12.28%	-7.50%	3.10%	5.10%	8.93%
NOPAT Q/Q Growth	0.00%	0.00%	-12.23%	5.15%	-11.57%	-7.84%	3.02%	5.99%	4.29%
Net Income Q/Q Growth	0.00%	0.00%	-11.82%	4.68%	-12.52%	-4.75%	2.33%	5.26%	8.82%
EPS Q/Q Growth	0.00%	0.00%	59.25%	12.93%	-17.54%	-2.28%	2.97%	5.76%	10.34%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-8.20%	-1.31%	-9.35%	21.24%	-15.80%	7.75%	6.86%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-3.20%	-9.48%	2.22%	5.76%	2.88%	-22.26%
Invested Capital Q/Q Growth	0.00%	0.00%	-4.24%	19.46%	11.89%	-2.96%	-4.46%	-2.69%	7.58%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	-123.09%	-26.59%	12.80%	31.85%	39.08%	41.38%	36.61%	42.61%	50.72%
EBITDA Margin	-496.15%	-254.24%	-191.18%	-148.30%	-109.48%	-107.75%	-79.32%	-61.36%	-16.85%
Operating Margin	-543.16%	-277.50%	-200.15%	-155.47%	-115.41%	-115.33%	-88.60%	-70.56%	-36.18%
EBIT Margin	-543.67%	-277.97%	-200.63%	-155.67%	-116.45%	-115.87%	-88.87%	-71.41%	-23.45%
Profit (Net Income) Margin	-550.85%	-280.16%	-197.98%	-155.31%	-114.94%	-107.02%	-83.48%	-66.69%	-20.63%
Tax Burden Percent	100.47%	100.34%	100.27%	100.27%	98.75%	95.44%	100.57%	100.27%	100.93%
Interest Burden Percent	100.84%	100.44%	98.41%	99.49%	99.96%	96.78%	93.41%	93.15%	87.13%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-548.12%	-383.56%	-269.74%	-137.50%	-84.51%	-53.20%	-63.97%	-50.08%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-486.62%	-352.31%	-249.59%	-125.63%	-73.60%	-40.70%	-46.30%	-56.35%
Return on Net Nonoperating Assets (RNNOA)	0.00%	388.15%	294.27%	212.43%	104.33%	52.71%	24.24%	25.88%	33.65%
Return on Equity (ROE)	0.00%	-159.97%	-89.30%	-57.31%	-33.17%	-31.80%	-28.97%	-38.08%	-16.43%
Cash Return on Invested Capital (CROIC)	0.00%	-748.12%	-402.12%	-350.31%	-206.32%	-177.03%	-54.11%	-26.42%	-45.57%
Operating Return on Assets (OROA)	0.00%	-61.04%	-72.07%	-47.88%	-27.99%	-28.36%	-25.07%	-32.14%	-14.06%
Return on Assets (ROA)	0.00%	-61.52%	-71.12%	-47.77%	-27.63%	-26.19%	-23.55%	-30.02%	-12.37%
Return on Common Equity (ROCE)	0.00%	361.79%	18.27%	-57.31%	-33.17%	-31.80%	-28.97%	-38.08%	-16.43%
Return on Equity Simple (ROE_SIMPLE)	0.00%	35.37%	-70.80%	-41.61%	-26.19%	-27.60%	-32.82%	-44.16%	0.00%
Net Operating Profit after Tax (NOPAT)	-41	-49	-76	-98	-107	-164	-152	-155	-95
NOPAT Margin	-380.21%	-194.25%	-140.10%	-108.83%	-80.79%	-80.73%	-62.02%	-49.39%	-25.33%
Net Nonoperating Expense Percent (NNEP)	0.00%	-61.50%	-31.25%	-20.15%	-11.87%	-10.91%	-12.50%	-17.67%	6.27%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-20.17%
Cost of Revenue to Revenue	223.09%	126.59%	87.20%	68.15%	60.92%	58.62%	63.39%	57.39%	49.28%
SG&A Expenses to Revenue	242.04%	170.88%	147.33%	114.61%	102.70%	104.61%	77.41%	69.78%	65.59%
R&D to Revenue	178.03%	80.02%	65.61%	47.73%	52.20%	59.10%	43.61%	29.03%	21.32%
Operating Expenses to Revenue	420.07%	250.90%	212.94%	187.32%	154.49%	156.71%	125.20%	113.17%	86.91%
Earnings before Interest and Taxes (EBIT)	-59	-71	-109	-140	-154	-236	-218	-223	-88
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-53	-65	-104	-134	-145	-219	-194	-192	-63
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	5.11	10.09	9.08	2.52	1.87	5.60	3.59
Price to Tangible Book Value (P/TBV)	0.00	0.00	5.17	10.13	9.76	3.09	2.41	7.11	4.50
Price to Revenue (P/Rev)	6.50	2.75	14.30	37.66	39.84	9.76	4.74	8.46	4.51
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	16.06	29.81	60.94	45.89	5.21	2.88	12.08	7.58
Enterprise Value to Revenue (EV/Rev)	0.00	11.38	11.90	34.49	36.25	7.28	3.37	7.57	3.75
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.11	0.05	0.01	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.08	0.03	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.80	-0.84	-0.85	-0.83	-0.72	-0.60	-0.56	-0.60
Leverage Ratio	0.00	1.30	1.26	1.20	1.20	1.21	1.23	1.27	1.33
Compound Leverage Factor	0.00	1.31	1.24	1.19	1.20	1.18	1.15	1.18	1.16
Debt to Total Capital	0.00%	9.84%	4.84%	1.39%	0.27%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	2.53%	2.09%	0.98%	0.27%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	7.31%	2.75%	0.41%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	294.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-203.91%	95.16%	98.61%	99.73%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	-0.15	-0.07	-0.04	-0.01	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	1.10	1.25	2.14	3.29	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	-0.11	-0.04	-0.01	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.20	-0.10	-0.05	-0.01	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	1.44	1.71	2.91	4.46	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	-0.15	-0.06	-0.01	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	-1.97	10.18	30.87	25.16	5.76	2.63	8.23	3.74
Noncontrolling Interest Sharing Ratio	0.00%	326.16%	120.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	5.16	5.28	9.29	8.67	6.58	5.79	4.88	3.64
Quick Ratio	0.00	4.65	4.95	8.78	8.03	6.01	5.19	4.38	3.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-67	-80	-127	-160	-344	-155	-64	-87
Operating Cash Flow to CapEx	-810.70%	-1,802.34%	-596.75%	-1,441.58%	-414.78%	-122.12%	-512.88%	-1,262.69%	-170.08%
Free Cash Flow to Firm to Interest Expense	0.00	-51.34	-61.73	-161.81	-437.12	-4,303.13	-30,922.66	-2,201.82	0.00
Operating Cash Flow to Interest Expense	-56.69	-50.39	-67.96	-180.76	-305.84	-1,554.81	-28,494.80	-2,210.14	0.00
Operating Cash Flow Less CapEx to Interest Expense	-63.68	-53.19	-79.35	-193.29	-379.58	-2,828.03	-34,050.60	-2,385.17	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.22	0.36	0.31	0.24	0.24	0.28	0.45	0.60
Accounts Receivable Turnover	0.00	4.69	6.21	4.68	4.82	5.91	5.81	7.93	8.19
Inventory Turnover	0.00	5.34	7.10	6.26	3.66	3.36	4.35	6.40	7.08
Fixed Asset Turnover	0.00	2.06	3.28	3.89	3.80	2.22	1.81	2.67	3.68
Accounts Payable Turnover	0.00	4.27	5.49	8.42	8.17	6.82	9.10	22.91	29.17
Days Sales Outstanding (DSO)	0.00	77.79	58.80	77.94	75.75	61.72	62.81	46.05	44.55
Days Inventory Outstanding (DIO)	0.00	68.35	51.40	58.31	99.80	108.75	83.83	57.04	51.52
Days Payable Outstanding (DPO)	0.00	85.40	66.54	43.36	44.66	53.52	40.10	15.93	12.51
Cash Conversion Cycle (CCC)	0.00	60.75	43.67	92.89	130.89	116.95	106.53	87.15	83.56
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	18	22	51	105	284	287	196	186
Invested Capital Turnover	0.00	2.82	2.74	2.48	1.70	1.05	0.86	1.30	1.98
Increase / (Decrease) in Invested Capital	0.00	18	3.69	29	54	180	2.60	-91	-8.58
Enterprise Value (EV)	0.00	289	647	3,108	4,796	1,481	826	2,371	1,412
Market Capitalization	70	70	778	3,393	5,273	1,986	1,163	2,647	1,699
Book Value per Share	$0.00	($72.12)	$4.67	$7.53	$11.78	$14.01	$10.86	$8.07	$7.84
Tangible Book Value per Share	$0.00	($72.78)	$4.62	$7.50	$10.96	$11.42	$8.42	$6.36	$6.25
Total Capital	0.00	99	160	341	582	789	623	473	473
Total Debt	0.00	9.72	7.73	4.74	1.55	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	7.22	4.40	1.40	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-71	-130	-285	-476	-505	-336	-276	-287
Capital Expenditures (CapEx)	6.33	3.67	15	9.87	27	102	28	5.08	28
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-1.12	-4.99	12	7.13	0.85	15	-0.63	9.13
Debt-free Net Working Capital (DFNWC)	0.00	80	133	302	485	506	351	276	242
Net Working Capital (NWC)	0.00	77	130	299	483	506	351	276	242
Net Nonoperating Expense (NNE)	18	22	31	42	45	54	53	54	-18
Net Nonoperating Obligations (NNO)	0.00	-71	-130	-285	-476	-505	-336	-276	-287
Total Depreciation and Amortization (D&A)	5.12	6.04	5.14	6.65	9.22	17	23	31	25
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-4.42%	-9.18%	13.51%	5.39%	0.42%	5.92%	-0.20%	2.42%
Debt-free Net Working Capital to Revenue	0.00%	313.19%	244.76%	335.38%	366.50%	248.48%	143.17%	88.11%	64.15%
Net Working Capital to Revenue	0.00%	303.35%	238.63%	331.68%	365.32%	248.48%	143.17%	88.11%	64.15%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($3.92)	($3.57)	($3.15)	$0.00	($3.60)	($3.60)	($1.30)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	33.12M	45.15M	49.63M	0.00	56.89M	58.02M	59.81M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($3.92)	($3.57)	($3.15)	$0.00	($3.60)	($3.60)	($1.30)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	33.12M	45.15M	49.63M	0.00	56.89M	58.02M	59.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($3.92)	($3.57)	($3.15)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	27.46M	39.19M	48.25M	0.00	57.67M	59.36M	61.15M
Normalized Net Operating Profit after Tax (NOPAT)	-41	-49	-76	-82	-107	-164	-141	-123	-95
Normalized NOPAT Margin	-380.21%	-194.25%	-140.10%	-91.35%	-80.79%	-80.73%	-57.40%	-39.34%	-25.33%
Pre Tax Income Margin	-548.25%	-279.21%	-197.44%	-154.88%	-116.39%	-112.14%	-83.01%	-66.51%	-20.43%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-64.68	-53.83	-84.32	-178.22	-419.88	-2,948.29	-43,565.20	-7,706.24	0.00
NOPAT to Interest Expense	-45.23	-37.62	-58.88	-124.59	-291.30	-2,054.29	-30,402.26	-5,330.40	0.00
EBIT Less CapEx to Interest Expense	-71.67	-56.63	-95.71	-190.76	-493.62	-4,221.50	-49,121.00	-7,881.28	0.00
NOPAT Less CapEx to Interest Expense	-52.23	-40.41	-70.27	-137.13	-365.04	-3,327.50	-35,958.06	-5,505.44	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-3.31%	0.00%	-1.73%	-7.13%	-3.56%	-2.15%	-1.90%	-0.02%

This table displays calculated financial ratios and metrics derived from Twist Bioscience's official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	61,148,026.00	122,623,408.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	61,148,026.00	122,623,408.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-0.50	-0.36
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	16.82%	31.81%	25.13%	27.81%	26.53%	24.08%	23.23%	17.91%	16.88%	16.89%	19.31%
EBITDA Growth	20.09%	1.67%	25.73%	-54.53%	24.30%	27.05%	13.18%	129.67%	25.34%	7.48%	-10.48%
EBIT Growth	12.17%	-4.96%	20.75%	-46.60%	23.86%	26.16%	14.82%	120.09%	22.64%	6.64%	-8.90%
NOPAT Growth	11.89%	-5.26%	20.68%	-46.30%	28.07%	26.25%	14.99%	52.06%	16.95%	5.03%	-10.35%
Net Income Growth	9.53%	-2.83%	23.10%	-49.09%	25.06%	26.54%	13.55%	123.83%	21.69%	3.44%	-11.93%
EPS Growth	11.96%	-1.35%	24.04%	-45.54%	27.16%	29.33%	16.46%	122.45%	25.42%	5.66%	-7.58%
Operating Cash Flow Growth	-1,534.10%	57.51%	56.14%	72.76%	26.00%	6.73%	33.14%	78.05%	22.89%	-15.80%	-35.21%
Free Cash Flow Firm Growth	82.85%	96.57%	115.19%	173.07%	273.83%	1,768.70%	258.63%	-103.25%	-118.47%	-160.01%	-217.80%
Invested Capital Growth	0.91%	-9.34%	-15.65%	-32.85%	-31.61%	-33.63%	-31.42%	-14.21%	-4.40%	10.10%	17.70%
Revenue Q/Q Growth	5.03%	6.80%	5.32%	8.18%	3.98%	4.73%	4.60%	3.52%	3.07%	4.74%	6.77%
EBITDA Q/Q Growth	19.89%	7.22%	-5.01%	-97.97%	60.76%	10.58%	-24.97%	167.66%	-198.84%	-10.80%	-49.70%
EBIT Q/Q Growth	17.09%	6.65%	-4.42%	-81.39%	56.94%	9.46%	-20.45%	142.79%	-265.90%	-9.25%	-40.89%
NOPAT Q/Q Growth	17.55%	6.25%	-4.07%	-81.89%	59.47%	3.88%	-19.96%	-2.57%	29.78%	-9.90%	-39.40%
Net Income Q/Q Growth	19.43%	7.00%	-5.78%	-88.10%	59.50%	8.83%	-24.48%	151.85%	-233.09%	-12.41%	-44.30%
EPS Q/Q Growth	19.80%	7.41%	-5.33%	-86.08%	59.86%	10.17%	-24.53%	150.00%	-233.33%	-13.64%	-42.00%
Operating Cash Flow Q/Q Growth	11.57%	-10.96%	15.45%	67.16%	-140.20%	-39.87%	39.40%	89.22%	-743.86%	-110.04%	29.24%
Free Cash Flow Firm Q/Q Growth	24.44%	88.94%	466.28%	138.74%	79.75%	6.16%	-21.28%	-102.16%	-946.66%	-237.13%	-54.53%
Invested Capital Q/Q Growth	-4.46%	-2.83%	-4.34%	-24.39%	-2.69%	-5.69%	-1.16%	-5.41%	7.58%	9.46%	5.66%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	36.63%	40.51%	41.01%	43.30%	45.14%	48.29%	49.60%	53.40%	51.35%	52.05%	51.59%
EBITDA Margin	-62.52%	-54.32%	-54.16%	-99.11%	-37.41%	-31.94%	-38.16%	24.94%	-23.92%	-25.30%	-35.47%
Operating Margin	-74.85%	-65.70%	-64.92%	-109.16%	-42.55%	-39.05%	-44.79%	-31.36%	-30.23%	-31.73%	-41.42%
EBIT Margin	-75.22%	-65.75%	-65.19%	-109.30%	-45.26%	-39.13%	-45.06%	18.63%	-29.98%	-31.27%	-41.27%
Profit (Net Income) Margin	-69.08%	-60.15%	-60.41%	-105.04%	-40.91%	-35.61%	-42.38%	21.23%	-27.41%	-29.42%	-39.76%
Tax Burden Percent	99.52%	100.28%	100.76%	100.22%	99.72%	100.31%	100.45%	99.07%	100.95%	100.84%	100.10%
Interest Burden Percent	92.27%	91.24%	91.97%	95.89%	90.63%	90.74%	93.64%	115.04%	90.57%	93.29%	96.26%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.93%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-44.95%	-41.15%	-43.26%	-89.84%	-38.57%	-38.90%	-48.47%	-60.06%	-41.84%	-44.72%	-59.62%
ROIC Less NNEP Spread (ROIC-NNEP)	-42.30%	-38.45%	-39.95%	-82.63%	-35.50%	-36.38%	-44.75%	-76.95%	-39.65%	-41.86%	-54.83%
Return on Net Nonoperating Assets (RNNOA)	25.19%	21.57%	21.52%	46.51%	19.85%	20.24%	24.63%	47.20%	23.68%	24.01%	30.43%
Return on Equity (ROE)	-19.76%	-19.57%	-21.74%	-43.33%	-18.73%	-18.66%	-23.84%	-12.86%	-18.16%	-20.71%	-29.19%
Cash Return on Invested Capital (CROIC)	-54.11%	-42.60%	-32.67%	-26.19%	-26.42%	-22.48%	-25.34%	-37.89%	-45.57%	-58.03%	-65.05%
Operating Return on Assets (OROA)	-21.22%	-21.00%	-23.24%	-44.55%	-20.37%	-19.26%	-24.13%	10.53%	-17.97%	-19.64%	-26.57%
Return on Assets (ROA)	-19.49%	-19.21%	-21.54%	-42.82%	-18.41%	-17.53%	-22.70%	12.00%	-16.43%	-18.48%	-25.60%
Return on Common Equity (ROCE)	-19.76%	-19.57%	-21.74%	-43.33%	-18.73%	-18.66%	-23.84%	-12.86%	-18.16%	-20.71%	-29.19%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-34.88%	-34.30%	-44.86%	0.00%	-43.28%	-43.43%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-35	-33	-34	-62	-25	-24	-29	-30	-21	-23	-32
NOPAT Margin	-52.40%	-45.99%	-45.45%	-76.41%	-29.78%	-27.34%	-31.35%	-31.07%	-21.16%	-22.21%	-29.00%
Net Nonoperating Expense Percent (NNEP)	-2.65%	-2.70%	-3.31%	-7.22%	-3.08%	-2.52%	-3.72%	16.90%	-2.19%	-2.86%	-4.80%
Return On Investment Capital (ROIC_SIMPLE)	-	-5.57%	-	-	-	-5.32%	-6.61%	-6.24%	-4.43%	-5.05%	-7.05%
Cost of Revenue to Revenue	63.37%	59.49%	58.99%	56.70%	54.86%	51.71%	50.40%	46.60%	48.65%	47.95%	48.41%
SG&A Expenses to Revenue	70.79%	73.90%	73.87%	69.72%	62.73%	63.32%	68.62%	65.97%	64.40%	67.25%	68.72%
R&D to Revenue	35.47%	32.31%	32.07%	27.58%	24.95%	24.02%	25.77%	18.79%	17.18%	16.52%	17.79%
Operating Expenses to Revenue	111.48%	106.21%	105.93%	152.45%	87.68%	87.34%	94.39%	84.76%	81.58%	83.77%	93.02%
Earnings before Interest and Taxes (EBIT)	-50	-47	-49	-89	-38	-35	-42	18	-30	-32	-46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-42	-39	-41	-81	-32	-28	-35	24	-24	-26	-39
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.87	3.59	3.54	5.84	5.60	6.05	5.32	4.61	3.59	4.25	6.40
Price to Tangible Book Value (P/TBV)	2.41	4.69	4.70	7.35	7.11	7.75	6.88	5.77	4.50	5.38	8.10
Price to Revenue (P/Rev)	4.74	8.06	7.15	9.72	8.46	8.35	6.74	6.08	4.51	4.95	7.12
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.88	6.47	6.34	12.79	12.08	13.44	11.39	10.97	7.58	8.28	12.42
Enterprise Value to Revenue (EV/Rev)	3.37	6.88	6.09	8.74	7.57	7.53	6.00	5.24	3.75	4.31	6.53
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.60	-0.56	-0.54	-0.56	-0.56	-0.56	-0.55	-0.61	-0.60	-0.57	-0.56
Leverage Ratio	1.23	1.23	1.23	1.26	1.27	1.28	1.30	1.32	1.33	1.37	1.42
Compound Leverage Factor	1.13	1.12	1.13	1.21	1.15	1.16	1.22	1.52	1.20	1.28	1.37
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	3.34	7.51	6.79	9.61	9.23	8.81	6.83	6.31	4.04	4.30	5.76
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.79	5.98	5.51	4.91	4.88	4.96	4.51	3.90	3.64	3.78	2.70
Quick Ratio	5.19	5.31	4.88	4.36	4.38	4.45	4.10	3.45	3.17	3.08	1.97
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-38	-4.17	15	36	65	70	55	-1.18	-12	-42	-64
Operating Cash Flow to CapEx	-865.19%	-1,525.43%	-3,221.06%	-660.93%	-765.23%	-944.80%	-313.37%	-15.28%	-95.07%	-248.79%	-136.25%
Free Cash Flow to Firm to Interest Expense	-37,679.70	0.00	0.00	0.00	2,258.58	2,897.22	382.77	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-20,704.00	0.00	0.00	0.00	-528.28	-892.83	-90.81	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-23,097.00	0.00	0.00	0.00	-597.31	-987.33	-119.79	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.28	0.32	0.36	0.41	0.45	0.49	0.54	0.57	0.60	0.63	0.64
Accounts Receivable Turnover	5.81	6.58	6.59	7.92	7.93	8.84	8.09	8.85	8.19	8.76	7.18
Inventory Turnover	4.35	4.47	4.87	5.42	6.40	6.73	7.23	6.76	7.08	6.71	7.22
Fixed Asset Turnover	1.81	1.94	2.07	2.39	2.67	2.91	3.18	3.59	3.68	3.81	3.93
Accounts Payable Turnover	9.10	11.47	16.35	18.67	22.91	21.83	23.51	19.76	29.17	18.95	17.26
Days Sales Outstanding (DSO)	62.81	55.50	55.36	46.10	46.05	41.27	45.11	41.23	44.55	41.66	50.85
Days Inventory Outstanding (DIO)	83.83	81.74	74.93	67.40	57.04	54.24	50.46	54.02	51.52	54.38	50.57
Days Payable Outstanding (DPO)	40.10	31.81	22.32	19.55	15.93	16.72	15.53	18.47	12.51	19.27	21.15
Cash Conversion Cycle (CCC)	106.53	105.43	107.97	93.94	87.15	78.80	80.04	76.77	83.56	76.77	80.27
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	287	279	267	202	196	185	183	173	186	204	215
Invested Capital Turnover	0.86	0.89	0.95	1.18	1.30	1.42	1.55	1.93	1.98	2.01	2.06
Increase / (Decrease) in Invested Capital	2.60	-29	-49	-99	-91	-94	-84	-29	-8.58	19	32
Enterprise Value (EV)	826	1,804	1,690	2,580	2,371	2,487	2,085	1,899	1,412	1,687	2,674
Market Capitalization	1,163	2,116	1,984	2,869	2,647	2,758	2,342	2,204	1,699	1,940	2,914
Book Value per Share	$10.86	$10.26	$9.69	$8.44	$8.07	$7.68	$7.38	$7.98	$7.84	$7.46	$7.42
Tangible Book Value per Share	$8.42	$7.84	$7.31	$6.71	$6.36	$6.00	$5.71	$6.38	$6.25	$5.90	$5.87
Total Capital	623	590	560	491	473	456	440	478	473	456	455
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-336	-311	-293	-289	-276	-271	-257	-305	-287	-252	-240
Capital Expenditures (CapEx)	2.39	1.51	0.60	0.97	2.00	2.27	4.14	9.17	12	9.97	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	15	14	11	-1.34	-0.63	4.84	6.32	1.91	9.13	25	32
Debt-free Net Working Capital (DFNWC)	351	325	304	288	276	276	263	253	242	223	203
Net Working Capital (NWC)	351	325	304	288	276	276	263	253	242	223	203
Net Nonoperating Expense (NNE)	11	10	11	23	9.42	7.34	10	-50	6.18	7.48	12
Net Nonoperating Obligations (NNO)	-336	-311	-293	-289	-276	-271	-257	-305	-287	-252	-240
Total Depreciation and Amortization (D&A)	8.50	8.17	8.30	8.30	6.66	6.38	6.40	6.07	6.00	6.19	6.41
Debt-free, Cash-free Net Working Capital to Revenue	5.92%	5.28%	3.98%	-0.46%	-0.20%	1.46%	1.82%	0.53%	2.42%	6.51%	7.76%
Debt-free Net Working Capital to Revenue	143.17%	123.87%	109.69%	97.58%	88.11%	83.49%	75.78%	69.76%	64.15%	57.06%	49.69%
Net Working Capital to Revenue	143.17%	123.87%	109.69%	97.58%	88.11%	83.49%	75.78%	69.76%	64.15%	57.06%	49.69%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.81)	($0.75)	($0.79)	($1.47)	($0.59)	($0.53)	($0.66)	$0.34	($0.45)	($0.50)	($0.71)
Adjusted Weighted Average Basic Shares Outstanding	56.89M	57.50M	57.78M	58.15M	58.02M	59.16M	59.65M	60.00M	59.81M	61.08M	61.70M
Adjusted Diluted Earnings per Share	($0.81)	($0.75)	($0.79)	($1.47)	($0.59)	($0.53)	($0.66)	$0.33	($0.44)	($0.50)	($0.71)
Adjusted Weighted Average Diluted Shares Outstanding	56.89M	57.50M	57.78M	58.15M	58.02M	59.16M	59.65M	61.16M	59.81M	61.08M	61.70M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	57.67M	57.82M	58.23M	58.59M	59.36M	59.65M	59.92M	60.36M	61.15M	61.31M	62.27M
Normalized Net Operating Profit after Tax (NOPAT)	-35	-33	-34	-31	-25	-24	-29	-30	-21	-23	-27
Normalized NOPAT Margin	-52.40%	-45.99%	-45.45%	-37.80%	-29.78%	-27.34%	-31.35%	-31.07%	-21.16%	-22.21%	-24.44%
Pre Tax Income Margin	-69.41%	-59.98%	-59.95%	-104.81%	-41.02%	-35.50%	-42.19%	21.43%	-27.15%	-29.18%	-39.72%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-50,357.00	0.00	0.00	0.00	-1,322.14	-1,446.38	-292.38	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-35,077.70	0.00	0.00	0.00	-870.00	-1,010.45	-203.44	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-52,750.00	0.00	0.00	0.00	-1,391.17	-1,540.88	-321.36	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-37,470.70	0.00	0.00	0.00	-939.04	-1,104.95	-232.42	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-2.15%	-2.83%	-3.18%	-2.31%	-1.90%	-0.79%	-0.01%	-0.03%	-0.02%	-0.02%	-0.02%

Financials Breakdown Chart

Key Financial Trends

Here is a concise four-year trend snapshot for Twist Bioscience (TWST), based on the quarterly cash flow statements, income statements, and balance sheets provided for 2023–2026. The bullets highlight key themes retail investors may care about when assessing the stock’s trajectory and liquidity profile.

Revenue growth: Quarterly operating revenue has risen from about $66.9 million in 2023 (Q4) to about $103.7 million in 2026 (Q1), reflecting a solid top-line uptrend over the period.
Gross margin expansion: Gross margin improved to roughly 52% in 2026 Q1 (gross profit ≈ $53.97 million on revenue ≈ $103.70 million), up from mid-30% levels in the earlier years.
Positive quarterly profitability in 2025: Twist posted a positive net income in 2025 Q3 (net income attributable to common shareholders ≈ $20.39 million; basic EPS ≈ $0.34, diluted EPS ≈ $0.33), marking a potential near-term profitability milestone.
Healthy liquidity position: At 2026 Q1, cash and equivalents were about $148.6 million and short-term investments roughly $49.4 million, totaling around $198 million in liquid assets to weather operating burn and fund R&D.
Solid balance-sheet cushion: Total equity ≈ $456.1 million against total liabilities ≈ $182.0 million, indicating a strong equity base and relatively light leverage for a high-R&D biotech company.
Financing activity support: Occasional equity issuances (e.g., 2025 Q4 and 2026 Q1) have provided liquidity without immediate debt obligations, though they introduce potential dilution for existing shareholders.
Non-cash adjustments in cash flows: Quarterly non-cash adjustments (depreciation and other items) are sizable in multiple periods, which can obscure the cash-flow signal if looked at in isolation.
Persistent net losses and negative operating cash flow: Despite revenue growth, net income remains negative in most periods (e.g., 2026 Q1 net income ≈ −$30.5 million) and cash flow from operating activities was about −$24.8 million in 2026 Q1, signaling ongoing cash burn.
Operating cash burn continues: Across several quarters, net cash from operating activities stayed negative, indicating that cash burn remains an ongoing risk relative to the company’s liquidity runway.
Investing cash outflows and capex pace: Net cash from investing activities in 2026 Q1 was negative (≈ −$9.93 million) with PPE purchases contributing to near-term cash outflows, limiting free cash flow generation from operations.

05/19/26 05:01 AM ETAI Generated. May Contain Errors.

Twist Bioscience Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Twist Bioscience's fiscal year ends in September. Their fiscal year 2025 ended on September 30, 2025.

Twist Bioscience's net income appears to be on an upward trend, with a most recent value of -$77.67 million in 2025, rising from -$59.31 million in 2017. The previous period was -$208.73 million in 2024. See where experts think Twist Bioscience is headed by visiting Twist Bioscience's forecast page.

Twist Bioscience's total operating income in 2025 was -$136.26 million, based on the following breakdown:

Total Gross Profit: $191.00 million
Total Operating Expenses: $327.26 million

Over the last 8 years, Twist Bioscience's total revenue changed from $10.77 million in 2017 to $376.57 million in 2025, a change of 3,397.5%.

Twist Bioscience's total liabilities were at $168.90 million at the end of 2025, a 19.3% increase from 2024, and a 531.9% increase since 2018.

In the past 7 years, Twist Bioscience's cash and equivalents has ranged from $46.74 million in 2019 to $465.83 million in 2021, and is currently $183.05 million as of their latest financial filing in 2025.

Over the last 8 years, Twist Bioscience's book value per share changed from 0.00 in 2017 to 7.84 in 2025, a change of 783.6%.

Related Companies

Financial statements for NASDAQ:TWST last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Twist Bioscience (TWST) Financials

Financials Breakdown Chart

Key Financial Trends

Twist Bioscience Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Twist Bioscience (TWST) Financials

Annual Income Statements for Twist Bioscience

Quarterly Income Statements for Twist Bioscience

Annual Cash Flow Statements for Twist Bioscience

Quarterly Cash Flow Statements for Twist Bioscience

Annual Balance Sheets for Twist Bioscience

Quarterly Balance Sheets for Twist Bioscience

Annual Metrics And Ratios for Twist Bioscience

Quarterly Metrics And Ratios for Twist Bioscience

Financials Breakdown Chart

Key Financial Trends

Twist Bioscience Financials - Frequently Asked Questions

When does Twist Bioscience's financial year end?

How has Twist Bioscience's net income changed over the last 8 years?

What is Twist Bioscience's operating income?

How has Twist Bioscience's revenue changed over the last 8 years?

How much debt does Twist Bioscience have?

How much cash does Twist Bioscience have?

How has Twist Bioscience's book value per share changed over the last 8 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools